(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 24.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Mirum Pharmaceuticals's revenue in 2026 is $521,312,000.On average, 13 Wall Street analysts forecast MIRM's revenue for 2026 to be $39,704,783,986, with the lowest MIRM revenue forecast at $37,254,914,336, and the highest MIRM revenue forecast at $41,665,283,122. On average, 12 Wall Street analysts forecast MIRM's revenue for 2027 to be $48,454,318,451, with the lowest MIRM revenue forecast at $41,987,507,357, and the highest MIRM revenue forecast at $53,335,351,850.
In 2028, MIRM is forecast to generate $60,764,008,319 in revenue, with the lowest revenue forecast at $52,360,231,319 and the highest revenue forecast at $72,409,940,400.